Jump to content

Draft:Steven A. Johnsen

From Wikipedia, the free encyclopedia

Steven A. Johnsen (Cancer Researcher)

[edit]
Professor Steven A. Johnsen
Born(1977-01-13)13 January 1977
Fargo, North Dakota
Alma mater
SpouseDr. Christin Johnsen
Scientific career
Fields
  • Cancer Research
  • Transcriptional Reprogramming
  • Epigenetic Regulation in Cancer

Steven A. Johnsen (born 13 January 1977 in Fargo) is an internationally recognized American molecular biologist and cancer researcher whose research has significantly advanced the understanding of transcriptional and epigenetic regulation in cancer. He is the inaugural Scientific Director of the Robert Bosch Center for Tumor Diseases (RBCT) in Stuttgart, Germany. Over two decades, Johnsen has published extensively on enhancer biology, chromatin regulation, and transcriptional reprogramming, with his findings contributing to the development of novel therapeutic strategies for cancers such as pancreatic ductal adenocarcinoma (PDAC), breast cancer, colorectal cancer, and more.

Early Life and Education

[edit]

Steven A. Johnsen was born in Fargo, North Dakota and raised in the Bitterroot Valley of western Montana, where he developed a deep appreciation for nature and a passion for horses.[1]

Johnsen earned his bachelor's degree in molecular biology from the University of Idaho in 1999. He pursued his doctoral studies at the Mayo Clinic in Rochester, Minnesota, where he obtained his Ph.D. in molecular biosciences in 2003 from the Mayo Clinic Graduate School of Biomedical Sciences.[2] His dissertation focused on the transcription factor KLF10 and its role in TGF-beta/Smad signaling, elucidating the regulation of Smad-dependent transcription and its implications for cancer.[3][4]

Postdoctoral Training

[edit]

2003–2006: Laboratory of Professor Ingolf Bach at the Center for Molecular Neurobiology Hamburg, Germany, where he explored transcriptional mechanisms and chromatin dynamics. Work was funded by the National Institutes of Health and the Alexander von Humboldt Foundation.[5][6]

2006–2007: Laboratory of Professor Frank Gannon at the European Molecular Biology Laboratory, then Director of the European Molecular Biology Organization, where he focused on transcriptional networks and the molecular drivers of cancer progression.

Academic Career

[edit]

Professorships

[edit]

Johnsen launched his independent research career as a W1 Assistant Professor in the Institute of Molecular Oncology at the University Medical Center Göttingen (2007–2012), where he began his pioneering studies on chromatin regulation and transcriptional control.[7]

2012–2014: W2 Associate Professor in the Institute for Tumor Biology at the University Medical Center Hamburg-Eppendorf.[8][9][10]

2014–2019: W3 Full Professor in the Department of General, Visceral, and Pediatric Surgery at the University Medical Center Göttingen, where he led a robust research program investigating the role of histone modifications and transcription factors in cancer biology.[11][12]

Mayo Clinic and Current Role

[edit]

In 2019, Johnsen joined the Mayo Clinic in Rochester, Minnesota, as a full professor in pharmacology and medicine. [13] [14] His research at Mayo Clinic focused on pancreatic cancer, specifically the epigenetic mechanisms driving therapy resistance.

Since 2022, Johnsen has served as the inaugural Scientific Director of the Robert Bosch Center for Tumor Diseases (RBCT), where his group investigates molecular mechanisms controlling cell identity, which the group aims to exploit for improving patient outcomes.[1]

On December 3, 2024, Johnsen was appointed Honorary Professor at the Medical Faculty of the Eberhard Karls University of Tübingen.[15][16][17] He currently lectures in the molecular biology curriculum for first year B.Sc. students majoring in Molecular Medicine.[18]

Research Interests and Contributions

[edit]

Johnsen has published over 100 papers and has an H-index of 42 (as of May 6, 2025).[19]

Epigenetic Regulation in Cancer

[edit]

Johnsen’s research has provided critical insights into epigenetic mechanisms, particularly the role of histone H2B monoubiquitination (H2Bub1) in transcriptional regulation, cancer progression, and cell identity. His work has demonstrated that H2Bub1 is a central regulator of chromatin dynamics, influencing transcription elongation, enhancer activity, and gene expression in various cellular contexts.[20]

Role of H2Bub1 in Differentiation and Cancer: His landmark study published in Molecular Cell (2012) back to back with the group of Prof. Moshe Oren revealed how H2Bub1 mediates chromatin transitions during stem cell differentiation and lineage specification.[21][22][23] These findings were further supported by extensive in vivo studies demonstrating a state-specific function of the H2B ubiquitin ligase in bone-forming osteoblasts.[24]

Cancer-Specific Roles of RNF40: Johnsen’s lab elucidated the functions of the H2Bub1 E3 ligase RNF40 in breast cancer, colorectal cancer, and inflammatory bowel disease (IBD). These studies demonstrated how RNF40-mediated H2Bub1 influences tumor suppressor gene expression, inflammation-associated pathways, and metastasis.[25][26][27][28][29][30][31]

Transcriptional Reprogramming in Pancreatic Cancer

[edit]

Since 2017, Johnsen’s research has focused on the transcriptional and epigenetic mechanisms driving pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with limited treatment options. Major contributions include:

Interactive Enhancer Hubs (iHUBs): Published in Gut (2023), this study identified highly connected enhancers, or iHUBs, that mediate transcriptional reprogramming and chemoresistance in PDAC.[32][33]

Subtype-Specific Enhancer Programs: His team identified the master transcription factors ΔNp63 and GATA6 as the central drivers of the highly aggressive basal-like and more differentiated classical molecular subtypes of pancreatic cancer. These studies go extensively beyond further work and demonstrate critical and differential functions of ΔNp63 and GATA6 in controlling enhancer-promoter interactions and gene expression.[34][35][3][4]

Enhancer Biology and BRD4

[edit]

Johnsen has made significant contributions to enhancer biology, particularly the roles of BRD4 and super-enhancers in cancer. His studies published in Nucleic Acids Research and Cell Reports highlight how BRD4 cooperates with transcription factors such as the estrogen receptor or ΔNp63 to activate oncogenic enhancers, promoting tumor growth and metastasis, and cell differentiation.[36][37][38][39]

Early Research on KLF10 (TIEG)

[edit]

Johnsen’s Ph.D. research focused on KLF10, a transcription factor critical for regulating TGF-beta/Smad signaling. His studies demonstrated how KLF10 represses inhibitory Smad7 to enhance Smad-dependent gene expression, with implications for cancer progression.[40][41]

Robert Bosch Center for Tumor Diseases

[edit]

The Robert Bosch Center for Tumor Diseases (RBCT) is a non-profit research institute dedicated to understanding the molecular mechanisms of cancer and improving patient treatment outcomes.[42][43][44] Located on the Bosch Health Campus in Stuttgart, Germany, the RBCT collaborates closely with the Robert Bosch Hospital and other research institutions.[45] Funded by the Robert Bosch Foundation, the RBCT focuses on translational research in areas such as epigenetics, transcriptional regulation, and the tumor microenvironment.[46]

Under Johnsen’s leadership, the RBCT has expanded its focus on developing innovative therapies to overcome therapy resistance and improve the molecular stratification of cancer patients.

Editor activities

[edit]

In addition to serving as a reviewer for most of the major molecular biology and cancer research journals, Johnsen is Associate Editor of the journal NAR Cancer and frequently serves as an ad hoc reviewer for many high level scientific journals such as Nature Cancer, Nature Communications, Cancer Research, Gut, Gastroenterology, Molecular Oncology, and many others..[47]

Personal Life

[edit]

Johnsen is married to Dr. Christin Johnsen, a physician specializing in congenital disorders of glycosylation. She works in the Department of Pediatric and Adolescent Medicine at the University Medical Center Göttingen. Together, they share a commitment to family, science, and equestrian activities.

During his youth, Johnsen actively participated in horse shows, excelling in various competitions. While his equestrian activities waned during his academic years, Johnsen later rekindled his involvement in 2020 alongside his family. Between 2020 and 2022, the Johnsen family maintained a small ranch in Minnesota, where he began competing in reining, a western riding discipline, with his American Quarter Horse and Paint Horse, A Special Nite Ryder. Since returning to Germany in 2022, the family no longer maintains a ranch but remains connected to equestrian activities. It was Johnsen’s passion for horse genetics that fueled his interest in biology and molecular genetics.

Selected Publications

[edit]
  • Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer (Gut 2025).[48]
  • Interactive Enhancer Hubs Mediate Transcriptional Reprogramming in Pancreatic Cancer (Gut, 2023).[37]
  • ΔNp63-Dependent Basal-Like Subtype-Specific Enhancers in PDAC (Molecular Cancer Research, 2023).[49]
  • H2B Monoubiquitination Controls Stem Cell Differentiation and Transcriptional Elongation (Molecular Cell, 2012).[22]
  • BRD4-Dependent Enhancer Regulation in Cancer (Nucleic Acids Research, 2017).[50]
  • RNF40-Mediated H2Bub1 in Breast and Colorectal Cancer (Cancer Research, 2021).[51]
  • Role of RNF40 in Bone Formation and IBD (Cell Death & Differentiation, 2021).[52]

References

[edit]
  1. ^ a b "Scientific Director, Prof. Dr. Steven A. Johnsen".
  2. ^ Öffentlichkeitsarbeit, Georg-August-Universität Göttingen-. "Johnsen, Steven, Prof. Dr. - Translational Cancer Research - Georg-August-University Göttingen". Georg-August Universität Göttingen (in German). Retrieved 2025-05-06.
  3. ^ a b Ekstrom, Thomas L.; Rosok, Raya M.; Abdelrahman, Amro M.; Parassiadis, Christina; Manjunath, Meghana; Dittrich, Marianna Y.; Wang, Xin; Kutschat, Ana P.; Kanakan, Akshay; Rajput, Ashish; Schacherer, Nadine; Lukic, Teodora; Carlson, Danielle M.; Thiel, Julia; Johnsen, Steven A. (2025-01-30). "Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer". Gut: gutjnl–2024–334374. doi:10.1136/gutjnl-2024-334374. ISSN 1468-3288. PMID 39884837.
  4. ^ a b Patil, Shilpa; Steuber, Benjamin; Kopp, Waltraut; Kari, Vijayalakshmi; Urbach, Laura; Wang, Xin; Küffer, Stefan; Bohnenberger, Hanibal; Spyropoulou, Dimitra; Zhang, Zhe; Versemann, Lennart; Bösherz, Mark Sebastian; Brunner, Marius; Gaedcke, Jochen; Ströbel, Philipp (2020-11-01). "EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6". Cancer Research. 80 (21): 4620–4632. doi:10.1158/0008-5472.CAN-20-0672. ISSN 1538-7445. PMID 32907838.
  5. ^ Steven, Johnsen. "Regulation of RLIM Activity by Phosphorylation". Grantome.
  6. ^ "Prof. Dr. Steven Johnsen". www.humboldt-foundation.de (in German). Retrieved 2025-03-18.
  7. ^ "Welcome to the Department of Molecular Oncology".
  8. ^ "10. Bericht der Gleichstellungsbeauftragten für das wissenschaftliche Personal und Studierende der Medizinischen Fakultät" (PDF).
  9. ^ "Tumor Biology".
  10. ^ "University Medical Center Hamburg-Eppendorf" (in German).
  11. ^ Öffentlichkeitsarbeit, Georg-August-Universität Göttingen-. "Mitte Oktober 2013 bis Mitte 31. März 2014 - Georg-August-University Göttingen". Georg-August Universität Göttingen (in German). Retrieved 2025-03-18.
  12. ^ "Universitätsmedizin Göttingen: Klinik für Allgemein-, Viszeral- und Kinderchirurgie".
  13. ^ "Habilitationen und Berufungen November 2018". www.forschung-und-lehre.de (in German). Retrieved 2025-03-18.
  14. ^ Öffentlichkeitsarbeit, Georg-August-Universität Göttingen-. "1. Juli 2018 bis 30. September 2018 - Georg-August-Universität Göttingen". Georg-August Universität Göttingen (in German). Retrieved 2025-03-18.
  15. ^ "Aktuelle Habilitationen und Berufungen". www.academics.de (in German). Retrieved 2025-03-17.
  16. ^ "Steven Johnsen zum Honorarprofessor an der Universität Tübingen ernannt". Bosch Health Campus (in German). Retrieved 2025-03-17.
  17. ^ "Steven Johnsen zum Honorarprofessor an der Universität Tübingen ernannt | Management-Krankenhaus". www.management-krankenhaus.de. Retrieved 2025-03-17.
  18. ^ "Molekulare Medizin - Bachelor (mono)" (in German).
  19. ^ "Web of Science - list of publications, Steven A. Johnsen".
  20. ^ "My Bibliography - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2025-05-06.
  21. ^ Karpiuk, Oleksandra; Najafova, Zeynab; Kramer, Frank; Hennion, Magali; Galonska, Christina; König, Annekatrin; Snaidero, Nicolas; Vogel, Tanja; Shchebet, Andrei; Begus-Nahrmann, Yvonne; Kassem, Moustapha; Simons, Mikael; Shcherbata, Halyna; Beissbarth, Tim; Johnsen, Steven A. (June 2012). "The Histone H2B Monoubiquitination Regulatory Pathway Is Required for Differentiation of Multipotent Stem Cells". Molecular Cell. 46 (5): 705–713. doi:10.1016/j.molcel.2012.05.022. ISSN 1097-2765. PMID 22681891.
  22. ^ a b Karpiuk, Oleksandra; Najafova, Zeynab; Kramer, Frank; Hennion, Magali; Galonska, Christina; König, Annekatrin; Snaidero, Nicolas; Vogel, Tanja; Shchebet, Andrei; Begus-Nahrmann, Yvonne; Kassem, Moustapha; Simons, Mikael; Shcherbata, Halyna; Beissbarth, Tim; Johnsen, Steven A. (2012-06-08). "The histone H2B monoubiquitination regulatory pathway is required for differentiation of multipotent stem cells". Molecular Cell. 46 (5): 705–713. doi:10.1016/j.molcel.2012.05.022. ISSN 1097-4164. PMID 22681891.
  23. ^ Fuchs, Gilad; Shema, Efrat; Vesterman, Rita; Kotler, Eran; Wolchinsky, Zohar; Wilder, Sylvia; Golomb, Lior; Pribluda, Ariel; Zhang, Feng; Haj-Yahya, Mahmood; Feldmesser, Ester; Brik, Ashraf; Yu, Xiaochun; Hanna, Jacob; Aberdam, Daniel (2012-06-08). "RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation". Molecular Cell. 46 (5): 662–673. doi:10.1016/j.molcel.2012.05.023. ISSN 1097-4164. PMC 3374598. PMID 22681888.
  24. ^ Najafova, Zeynab; Liu, Peng; Wegwitz, Florian; Ahmad, Mubashir; Tamon, Liezel; Kosinsky, Robyn Laura; Xie, Wanhua; Johnsen, Steven A.; Tuckermann, Jan (February 2021). "RNF40 exerts stage-dependent functions in differentiating osteoblasts and is essential for bone cell crosstalk". Cell Death and Differentiation. 28 (2): 700–714. doi:10.1038/s41418-020-00614-w. ISSN 1476-5403. PMC 7862367. PMID 32901120.
  25. ^ Prenzel, Tanja; Begus-Nahrmann, Yvonne; Kramer, Frank; Hennion, Magali; Hsu, Chieh; Gorsler, Theresa; Hintermair, Corinna; Eick, Dirk; Kremmer, Elisabeth; Simons, Mikael; Beissbarth, Tim; Johnsen, Steven A. (2011-09-01). "Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B". Cancer Research. 71 (17): 5739–5753. doi:10.1158/0008-5472.CAN-11-1896. ISSN 1538-7445. PMID 21862633.
  26. ^ Wegwitz, Florian; Prokakis, Evangelos; Pejkovska, Anastasija; Kosinsky, Robyn Laura; Glatzel, Markus; Pantel, Klaus; Wikman, Harriet; Johnsen, Steven A. (2020-10-17). "The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis". Cell Death & Disease. 11 (10): 873. doi:10.1038/s41419-020-03081-w. ISSN 2041-4889. PMC 7568723. PMID 33070155.
  27. ^ Prokakis, Evangelos; Jansari, Shaishavi; Boshnakovska, Angela; Wiese, Maria; Kusch, Kathrin; Kramm, Christof; Dullin, Christian; Rehling, Peter; Glatzel, Markus; Pantel, Klaus; Wikman, Harriet; Johnsen, Steven A.; Gallwas, Julia; Wegwitz, Florian (2023-09-28). "RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer". Cell Death & Disease. 14 (9): 641. doi:10.1038/s41419-023-06157-5. ISSN 2041-4889. PMC 10539310. PMID 37770435.
  28. ^ Kosinsky, Robyn Laura; Chua, Robert Lorenz; Qui, Martin; Saul, Dominik; Mehlich, Dawid; Ströbel, Philipp; Schildhaus, Hans-Ulrich; Wegwitz, Florian; Faubion, William A.; Johnsen, Steven A. (2019-03-26). "Loss of RNF40 Decreases NF-κB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice". Journal of Crohn's & Colitis. 13 (3): 362–373. doi:10.1093/ecco-jcc/jjy165. ISSN 1876-4479. PMC 6599279. PMID 30321325.
  29. ^ Schneider, Deborah; Chua, Robert Lorenz; Molitor, Nicole; Hamdan, Feda H.; Rettenmeier, Eva Maria; Prokakis, Evangelos; Mishra, Vivek Kumar; Kari, Vijayalakshmi; Wegwitz, Florian; Johnsen, Steven A.; Kosinsky, Robyn Laura (2019-07-02). "The E3 ubiquitin ligase RNF40 suppresses apoptosis in colorectal cancer cells". Clinical Epigenetics. 11 (1): 98. doi:10.1186/s13148-019-0698-x. ISSN 1868-7083. PMC 6604314. PMID 31266541.
  30. ^ Kosinsky, Robyn Laura; Chua, Robert Lorenz; Qui, Martin; Saul, Dominik; Mehlich, Dawid; Ströbel, Philipp; Schildhaus, Hans-Ulrich; Wegwitz, Florian; Faubion, William A.; Johnsen, Steven A. (2019-03-26). "Loss of RNF40 Decreases NF-κB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice". Journal of Crohn's & Colitis. 13 (3): 362–373. doi:10.1093/ecco-jcc/jjy165. ISSN 1876-4479. PMC 6599279. PMID 30321325.
  31. ^ Kosinsky, Robyn Laura; Zerche, Maria; Kutschat, Ana Patricia; Nair, Asha; Ye, Zhenqing; Saul, Dominik; von Heesen, Maximilian; Friton, Jessica J.; Schwarzer, Ana Carolina; Paglilla, Nadia; Sheikh, Shehzad Z.; Wegwitz, Florian; Sun, Zhifu; Ghadimi, Michael; Newberry, Rodney D. (November 2021). "RNF20 and RNF40 regulate vitamin D receptor-dependent signaling in inflammatory bowel disease". Cell Death and Differentiation. 28 (11): 3161–3175. doi:10.1038/s41418-021-00808-w. ISSN 1476-5403. PMC 8563960. PMID 34088983.
  32. ^ "Gut Journal".
  33. ^ Hamdan, Feda H.; Abdelrahman, Amro M.; Kutschat, Ana Patricia; Wang, Xin; Ekstrom, Thomas L.; Jalan-Sakrikar, Nidhi; Wegner Wippel, Catherine; Taheri, Negar; Tamon, Liezel; Kopp, Waltraut; Aggrey-Fynn, Joana; Bhagwate, Aditya V.; Alva-Ruiz, Roberto; Lynch, Isaac; Yonkus, Jennifer (June 2023). "Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer". Gut. 72 (6): 1174–1185. doi:10.1136/gutjnl-2022-328154. ISSN 1468-3288. PMC 10402638. PMID 36889906.
  34. ^ Hamdan, Feda H.; Johnsen, Steven A. (2018-12-26). "DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network". Proceedings of the National Academy of Sciences of the United States of America. 115 (52): E12343 – E12352. Bibcode:2018PNAS..11512343H. doi:10.1073/pnas.1812915116. ISSN 1091-6490. PMC 6310858. PMID 30541891.
  35. ^ Wang, Xin; Kutschat, Ana P.; Aggrey-Fynn, Joana; Hamdan, Feda H.; Graham, Rondell P.; Wixom, Alexander Q.; Souto, Yara; Ladigan-Badura, Swetlana; Yonkus, Jennifer A.; Abdelrahman, Amro M.; Alva-Ruiz, Roberto; Gaedcke, Jochen; Ströbel, Philipp; Kosinsky, Robyn Laura; Wegwitz, Florian (2023-09-01). "Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma". Molecular Cancer Research: MCR. 21 (9): 881–891. doi:10.1158/1541-7786.MCR-22-0916. ISSN 1557-3125. PMC 10542885. PMID 37279184.
  36. ^ Nagarajan, Sankari; Hossan, Tareq; Alawi, Malik; Najafova, Zeynab; Indenbirken, Daniela; Bedi, Upasana; Taipaleenmäki, Hanna; Ben-Batalla, Isabel; Scheller, Marina; Loges, Sonja; Knapp, Stefan; Hesse, Eric; Chiang, Cheng-Ming; Grundhoff, Adam; Johnsen, Steven A. (2014-07-24). "Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription". Cell Reports. 8 (2): 460–469. doi:10.1016/j.celrep.2014.06.016. ISSN 2211-1247. PMC 4747248. PMID 25017071.
  37. ^ a b Wang, Xin; Kutschat, Ana P.; Yamada, Moyuru; Prokakis, Evangelos; Böttcher, Patricia; Tanaka, Koji; Doki, Yuichiro; Hamdan, Feda H.; Johnsen, Steven A. (July 2021). "Bromodomain protein BRDT directs ΔNp63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas". Cell Death and Differentiation. 28 (7): 2207–2220. doi:10.1038/s41418-021-00751-w. ISSN 1476-5403. PMC 8257622. PMID 33658703.
  38. ^ Najafova, Zeynab; Tirado-Magallanes, Roberto; Subramaniam, Malayannan; Hossan, Tareq; Schmidt, Geske; Nagarajan, Sankari; Baumgart, Simon J.; Mishra, Vivek Kumar; Bedi, Upasana; Hesse, Eric; Knapp, Stefan; Hawse, John R.; Johnsen, Steven A. (2017-01-09). "BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire". Nucleic Acids Research. 45 (1): 127–141. doi:10.1093/nar/gkw826. ISSN 1362-4962. PMC 5224504. PMID 27651452.
  39. ^ Nagarajan, Sankari; Bedi, Upasana; Budida, Anusha; Hamdan, Feda H.; Mishra, Vivek Kumar; Najafova, Zeynab; Xie, Wanhua; Alawi, Malik; Indenbirken, Daniela; Knapp, Stefan; Chiang, Cheng-Ming; Grundhoff, Adam; Kari, Vijayalakshmi; Scheel, Christina H.; Wegwitz, Florian (2017-04-07). "BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells". Nucleic Acids Research. 45 (6): 3130–3145. doi:10.1093/nar/gkw1276. ISSN 1362-4962. PMC 5389510. PMID 27980063.
  40. ^ Johnsen, Steven A.; Subramaniam, Malayannan; Monroe, David G.; Janknecht, Ralf; Spelsberg, Thomas C. (2002-08-23). "Modulation of transforming growth factor beta (TGFbeta)/Smad transcriptional responses through targeted degradation of TGFbeta-inducible early gene-1 by human seven in absentia homologue". The Journal of Biological Chemistry. 277 (34): 30754–30759. doi:10.1074/jbc.M204812200. ISSN 0021-9258. PMID 12072443.
  41. ^ Johnsen, Steven A.; Subramaniam, Malayannan; Janknecht, Ralf; Spelsberg, Thomas C. (2002-08-22). "TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses". Oncogene. 21 (37): 5783–5790. doi:10.1038/sj.onc.1205681. ISSN 0950-9232. PMID 12173049.
  42. ^ "RBCT website". Retrieved 2025-01-24.
  43. ^ "Bündnis gegen Krebs in Stuttgart gegründet" (in German).
  44. ^ "Bosch schmiedet Bündnis gegen Krebs" (in German).
  45. ^ "Bosch Health Campus".
  46. ^ "Habilitationen und Berufungen März 2025". www.forschung-und-lehre.de (in German). Retrieved 2025-04-16.
  47. ^ "Editorial Board - NAR Cancer".
  48. ^ Ekstrom, Thomas L.; Rosok, Raya M.; Abdelrahman, Amro M.; Parassiadis, Christina; Manjunath, Meghana; Dittrich, Marianna Y.; Wang, Xin; Kutschat, Ana P.; Kanakan, Akshay; Rajput, Ashish; Schacherer, Nadine; Lukic, Teodora; Carlson, Danielle M.; Thiel, Julia; Kopp, Waltraut; Stroebel, Philipp; Ellenrieder, Volker; Gaedcke, Jochen; Dong, Meng; Najafova, Zeynab; Truty, Mark J.; Hessmann, Elisabeth; Johnsen, Steven A. (2025). "Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer". Gut. doi:10.1136/gutjnl-2024-334374. PMID 39884837.
  49. ^ Wang, Xin; Kutschat, Ana P.; Aggrey-Fynn, Joana; Hamdan, Feda H.; Graham, Rondell P.; Wixom, Alexander Q.; Souto, Yara; Ladigan-Badura, Swetlana; Yonkus, Jennifer A.; Abdelrahman, Amro M.; Alva-Ruiz, Roberto; Gaedcke, Jochen; Ströbel, Philipp; Kosinsky, Robyn Laura; Wegwitz, Florian (2023-09-01). "Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma". Molecular Cancer Research. 21 (9): 881–891. doi:10.1158/1541-7786.MCR-22-0916. ISSN 1541-7786. PMC 10542885. PMID 37279184.
  50. ^ Mishra, Vivek Kumar; Wegwitz, Florian; Kosinsky, Robyn Laura; Sen, Madhobi; Baumgartner, Roland; Wulff, Tanja; Siveke, Jens T.; Schildhaus, Hans-Ulrich; Najafova, Zeynab; Kari, Vijayalakshmi; Kohlhof, Hella; Hessmann, Elisabeth; Johnsen, Steven A. (2017-06-20). "Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner". Nucleic Acids Research. 45 (11): 6334–6349. doi:10.1093/nar/gkx212. ISSN 0305-1048. PMC 5499659. PMID 28369619.
  51. ^ Wegwitz, Florian; Prokakis, Evangelos; Pejkovska, Anastasija; Kosinsky, Robyn Laura; Glatzel, Markus; Pantel, Klaus; Wikman, Harriet; Johnsen, Steven A. (2020-10-17). "The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis". Cell Death & Disease. 11 (10): 873. doi:10.1038/s41419-020-03081-w. ISSN 2041-4889. PMC 7568723. PMID 33070155.
  52. ^ Kosinsky, Robyn Laura; Chua, Robert Lorenz; Qui, Martin; Saul, Dominik; Mehlich, Dawid; Ströbel, Philipp; Schildhaus, Hans-Ulrich; Wegwitz, Florian; Faubion, William A; Johnsen, Steven A (2019-03-26). "Loss of RNF40 Decreases NF-κB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice". Journal of Crohn's and Colitis. 13 (3): 362–373. doi:10.1093/ecco-jcc/jjy165. ISSN 1873-9946. PMC 6599279. PMID 30321325.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Steven_A._Johnsen&oldid=1290373348"